Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT) from its SEC filings: 2020 revenue $7.9 million (-65% vs the year before), net margin -950%, free cash flow -$35.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2020) | $7.9 million |
| Revenue growth | -65% |
| Net income | -$74.8 million |
| Net margin | -950.4% |
| Free cash flow | -$35.9 million |
| Latest quarter (Q3 2020 (calendar)) revenue vs a year earlier | -69% |
| Cash | $181.2 million |
| Long-term debt | $44.2 million |
| Share count, 1 year | +24% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.